MYC and chronic myelogenous leukemia, BCR-ABL1 positive: Whereas imatinib or c-Myc inhibitor (+)-JQ1 (JQ1) treatment can successively induce the activities of both wild type and ChoRE-mutant TXNIP promoter dose-dependently (Fig. 2C, D), indicating c-Myc mediated imatinib suppression of TXNIP is not predominantly through the competitive binding of c-Myc with MondoA on TXNIP promoter in CML cells.